Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07728721) titled 'Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis' on July 22.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Haisco Pharmaceutical Group Co., Ltd.

Condition: Idiopathic Pulmonary Fibrosis (IPF)

Intervention: Drug: HSK50042 dose 1 Drug: HSK50042 dose 2 Drug: HSK50042 dose 3

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: August 25, 2026

Target Sample ...